Source comparison
CJC-1295 vs Other Growth Hormone Secretagogues
| Compound | Mechanism | Half-Life | Dosing Frequency | IGF-1 Increase (Mean) | Primary Advantage for Women Over 40 | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 1–2x weekly | +35–60% from baseline | Sustain
This comparison does not assign a generated winner or score.
- | Compound | Mechanism | Half-Life | Dosing Frequency | IGF-1 Increase (Mean) | Primary Advantage for Women Over 40 | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 1–2x weekly | +35–60% from baseline | Sustained GH pulse extension without daily injections. Practical for long-term use | Best for women prioritizing adherence and natural pulsatility preservation || Ipamorelin | Ghrelin receptor agonist | 2 hours | 2–3x daily | +20–30% (acute spikes) | Minimal cortisol or prolactin elevation. Cleanest ghrelin mimetic available | Ideal when combined with CJC-1295 for synergistic pulsatile amplification || MK 677 | Oral ghrelin mimetic | 24 hours | Once daily | +40–90% sustained | Oral administration, consistent GH elevation throughout the day | Convenient but elevates ghrelin (increased appetite). Problematic for fat loss phases || Sermorelin | GHRH analogue (no DAC) | 8–12 minutes | 2–3x daily | +25–40% (pulsatile only) | Preserves natural
- CJC-1295 occupies a unique position: it extends natural GH pulses without the appetite surge of MK 677, the injection frequency burden of sermorelin, or the regulatory limitations of tesamorelin. For women over 40 seeking metabolic support without daily administration, CJC-1295 with DAC represents the most practical option. The CJC1295 Ipamorelin 5MG 5MG combination available through research suppliers exemplifies the synergistic approach many protocols use. Pairing sustained GHRH stimulation (CJC-1295) with acute ghrelin receptor activation (ipamorelin) for maximal pulsatile amplitude.